Company Filing History:
3 out of 41 
1 out of 1,743 
1 out of 5,081 
Years Active: 2023-2025
Title: Yanqun Shu: Innovator in Neuromuscular Research
Introduction
Yanqun Shu is a prominent inventor based in Winchester, MA, known for his significant contributions to the field of neuromuscular research. He holds three patents that focus on innovative methods for treating conditions related to frataxin deficiency, particularly Friedreich's ataxia.
Latest Patents
One of his latest patents is titled "Frataxin expression constructs having engineered promoters and methods of use thereof." This patent discloses compositions and methods for enhancing the expression of frataxin (FXN) both in vitro and in vivo. The methods include the use of engineered promoters and delivery via adeno-associated viral (AAV) particles. These compositions are particularly useful in treating subjects diagnosed with Friedreich's ataxia or other neurological conditions associated with frataxin deficiency. Another notable patent is "Rescue of central and peripheral neurological phenotype of Friedreich's ataxia by intravenous delivery." This patent describes methods for treating Friedreich's Ataxia using AAV to deliver therapeutic agents effectively.
Career Highlights
Yanqun Shu has worked with several notable organizations throughout his career. He has been associated with Voyager Therapeutics, Inc., where he contributed to advancing therapeutic solutions for neurological disorders. Additionally, he has worked with the Institut National De La Santé Et De La Recherche Médicale, further enhancing his expertise in medical research.
Collaborations
Yanqun Shu has collaborated with esteemed colleagues, including Dinah Wen-Yee Sah and Jinzhao Hou, to further his research and development efforts in the field of neuromuscular diseases.
Conclusion
Yanqun Shu's innovative work in the area of frataxin-related therapies showcases his commitment to advancing medical science and improving the lives of individuals affected by neuromuscular disorders. His patents reflect a significant step forward in the treatment of Friedreich's ataxia and similar conditions.